Orbis Medicines Expands R&D Operations in Copenhagen
Orbis Medicines, a forefront player in oral macrocycle drug discovery, is excited to announce a pivotal expansion of its research and development (R&D) capabilities. The company will establish a new site at Symbion’s state-of-the-art biotech hub in Copenhagen, a city recognized for its vibrant start-up ecosystem and innovation.
New Opportunities at Symbion's Biotech Hub
This location is poised to accommodate additional R&D personnel and executive team members, further enhancing Orbis’ existing infrastructure in Lausanne, Switzerland. This strategic move is part of a broader initiative to solidify the company’s leadership in the development of pioneering oral macrocycle therapeutics, which are essential for advancing medical treatments.
Access to Premier Expertise and Resources
By establishing its presence in Copenhagen, Orbis will be tapping into unparalleled expertise in peptide chemistry and drug discovery, benefiting from collaborations with multinational pharmaceutical and biotech companies that are based in the area. The integration of advanced technologies like AI and machine learning into Orbis’ research framework will further position the company as an innovator in the medicinal chemistry field.
Leveraging the Danish Centre for AI Innovation
In a move to bolster its capabilities, Orbis will also gain access to the recently established Danish Centre for AI Innovation. This center offers a world-class supercomputer, Gefion, which will significantly enhance Orbis' research capabilities, allowing for more streamlined development processes in macrocycle drug creation.
A Testimony to Growth and Innovation
Morten Døssing, Executive Chair of the Orbis Board and a partner at Novo Holdings, expressed pride in the company’s growth and the allure of Copenhagen's lifestyle. He emphasized that the Fuglebakken site, with its historical ties to innovation and development within Novo Nordisk, presents the perfect backdrop for Orbis’ next growth phase.
A Robust Pipeline of Development
With recent seed financing from prominent life sciences investors Novo Holdings and Forbion, Orbis is investing heavily in its pioneering
The Promise of Macrocycles
Macrocycles represent a vast and diverse group of compounds known for their therapeutic properties, including exceptional structural flexibility. The
Strategic Hiring for Future Success
The new Copenhagen site is set to add over 15 experienced professionals, covering various specialties such as platform chemistry, biology, and drug metabolism research. This recruitment drive is aimed at nurturing a talented workforce ready to advance the innovative agenda of Orbis Medicines and bring forward groundbreaking treatments.
About Orbis Medicines
Orbis Medicines is a biotech company dedicated to advancing oral macrocycle drug discovery. By harnessing the power of its
About the Gen Platform
The
Frequently Asked Questions
What is Orbis Medicines known for?
Orbis Medicines is known for its pioneering work in oral macrocycle drug discovery, focusing on creating effective oral alternatives to biologic drugs.
Where is the new Orbis R&D site located?
The new R&D site is located at Symbion's biotech hub in Copenhagen, Denmark, enhancing their operational capabilities.
How many professionals is Orbis looking to hire?
Orbis aims to hire over 15 experienced technical professionals for their new site in Copenhagen.
What technology does Orbis use in its drug development process?
Orbis incorporates AI and machine learning within its
What therapeutic area does Orbis focus on?
Orbis focuses on developing oral macrocycle candidates that target a wide range of diseases and medical conditions.
